Predictive markers of endocrine response in breast cancer
Author:
Publisher
Baishideng Publishing Group Inc.
Subject
Internal Medicine
Reference53 articles.
1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
2. Tamoxifen in the Treatment of Breast Cancer
3. Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
4. A Review of Fulvestrant in Breast Cancer
5. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies;Biochemical Pharmacology;2024-05
2. BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer;Clinical Breast Cancer;2024-02
3. Heterogeneity in hormone-dependent breast cancer and therapy: Steroid hormones, HER2, melanoma antigens, and cannabinoid receptors;Advances in Cancer Biology - Metastasis;2023-07
4. Effect of combining CBD with standard breast cancer therapeutics;Advances in Cancer Biology - Metastasis;2022-07
5. Prognostic Factors Effective on Survival in Unifocal Borderline Luminal B HER2-Negative and Triple-Negative Breast Cancers: a Cross-Sectional Study;Indian Journal of Surgery;2022-01-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3